Bisphosphonates May Improve Outcomes in Patients with RCC and Bone Metastases

Share this article:

SAN FRANCISCO—Combining a bisphosphonate with sunitinib may improve progression-free survival (PFS) and overall survival (OS) in patients with bone metastases from renal cell carcinoma (RCC), that are treated with sunitinib, according to a multicenter, retrospective study presented at the 2012 Genitourinary Cancer Symposium.

Bisphosphonates can prevent skeletal events related to bone metastases, but the findings from this study suggest bisphosphonates also may have anti-tumor effects in this patient population, said lead investigator Daniel Keizman, MD, head of the Genitourinary Oncology Service at Meir Medical Center in Kfar-Saba, Israel, who presented the study findings.

For this investigation, he and his colleagues evaluated whether a bisphosphonate can improve the response rates, PFS, and OS in patients with RCC and bone metastases treated with sunitinib.  Patients were divided into bisphosphonate users (Group 1) and non-users (Group 2). 

From 2004-2011, 209 patients with metastatic RCC were treated with sunitinib. Of these, 76 patients had bone metastases (35 patients in Group 1 and 41 in Group 2). The groups were balanced in terms of known prognostic factors. The patients were also balanced with regard to past cytokines/targeted treatments, and mean sunitinib dose/cycle. Objective response was partial response/stable disease in 30 patients (86%) in Group 1 compared with 29 patients (71%) in Group 2. Moreover, disease refractory to sunitinib treatment occurred in five patients (14%) of Group 1 compared with 12 patients (29%) of Group 2. The median PFS was 15 months for Group 1 compared with five months for Group 2. Median OS was not reached (with a median follow-up of 45 months) for group 1 versus 14 months for group 2.

“We found that the use of bisphosphonates decreased the risk of disease progression by 45% and of dying by approximately 60%,” Dr. Keizman said.

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Genitourinary Cancers Symposium

Sign Up for Free e-newsletters

More in Genitourinary Cancers Symposium

Diabetes Ups Kidney Cancer Patient Death Risk

Diabetes Ups Kidney Cancer Patient Death Risk

Diabetes also found to increase cancer-specific mortality in patients with clear cell renal cell carcinoma.

Prostate Cancer Expectant Management On the Rise

Prostate Cancer Expectant Management On the Rise

Patients diagnosed with the cancer in 2011 were 2.5 times more likely to be managed expectantly than those diagnosed in 2004.

Kidney Cancer Survival Improved by BP Drugs

Kidney Cancer Survival Improved by BP Drugs

ACE inhibitors and angiotensin receptor blockers were shown to prolong median overall survival by nine months.